Title: Transgenic mice expressing individual Abeta peptides. Transgenic mouse models have been developed that deposit Abeta in the brain. However, to generate sufficient Abeta to cause amyloid deposition current models overexpress human mutant APP at levels at least 3-5 fold greater than endogenous mouse APP. Thus, any study of the role of Abeta deposition in AD using current transgenic mice is potentially confounded by overexpression of APP. At present there are no animal models that generate Abeta in the secretory pathway, in the absence of APP overexpression, at levels sufficient to cause amyloid pathology. This is significant because accumulation and deposition of Abeta, in AD, occurs in the absence of APP overexpression. To develop a system where individual Abeta peptides are efficiently expressed and secreted without APP overexpression, we created transgenic mice that express BRI-Abeta, fusion proteins. The fusion is between the BRI protein involved in amyloid deposition in Familial British Dementia and Abeta1- 40/42. Initial characterization of mice that express either BRI-Abeta1-40 or BRI-Abeta1-42 indicate that Abeta40 or Abeta42 levels are elevated, respectively, to levels equivalent to APP695NL (Tg2576) mice. In this proposal, we will test the hypothesis that overproduction of secreted Abeta will induce similar amyloid deposition to mutant APP mice and that, in the absence of sAPP overexpression, this will recapitulate more fully the pathology seen in AD. In addition, by comparing mice that generate Abeta40 and Abeta42 alone with bigenic mice expressing both Abeta40 and Abeta42 we will examine the role of individual Abeta peptides in development of amyloid pathology.
The specific aims are: (1). To characterize BRI-AIbeta42 and BRI-Abeta40 mice and determine the time course of Abeta accumulation and associated pathology; (2). To examine the respective roles of Abeta40 and Abeta42 in seeding Abeta deposition, plaque growth and other pathology by examining the temporal course of Abeta deposition in bigenic mice from the following crosses a) BRI-Abeta40 X BRI-Abeta42 mice; b) BRI-Abeta40 X APP695 wt (Tg5649) and APP695 NL (Tg2576) mice; c) BRI-Abeta42 X APP695 wt and APP695 NL mice. (3). To assess whether behavioral alterations occur in BRI-Abeta40 and BRI-Abeta42 mice and determine the relationship of any observed behavioral alterations with the pathological changes observed.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG022595-04
Application #
7118056
Study Section
Special Emphasis Panel (ZRG1-BDCN-4 (01))
Program Officer
Snyder, Stephen D
Project Start
2003-09-30
Project End
2007-08-31
Budget Start
2006-09-01
Budget End
2007-08-31
Support Year
4
Fiscal Year
2006
Total Cost
$294,747
Indirect Cost
Name
Mayo Clinic Jacksonville
Department
Type
DUNS #
153223151
City
Jacksonville
State
FL
Country
United States
Zip Code
32224
Matsuda, Shuji; Giliberto, Luca; Matsuda, Yukiko et al. (2008) BRI2 inhibits amyloid beta-peptide precursor protein processing by interfering with the docking of secretases to the substrate. J Neurosci 28:8668-76
Ahmed, Zeshan; Shaw, Gerry; Sharma, Ved P et al. (2007) Actin-binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry. J Histochem Cytochem 55:687-700
Kim, Jungsu; Onstead, Luisa; Randle, Suzanne et al. (2007) Abeta40 inhibits amyloid deposition in vivo. J Neurosci 27:627-33
Levites, Yona; Smithson, Lisa A; Price, Robert W et al. (2006) Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB J 20:2576-8
McGowan, Eileen; Eriksen, Jason; Hutton, Michael (2006) A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 22:281-9
Matsuda, Shuji; Giliberto, Luca; Matsuda, Yukiko et al. (2005) The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production. J Biol Chem 280:28912-6
McGowan, Eileen; Pickford, Fiona; Kim, Jungsu et al. (2005) Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47:191-9